Grufity logo
Grufity logo
AUPH

AUPH - Aurinia Pharmaceuticals Inc Stock Price, Fair Value and News

$18.60+0.72 (+4.03%)
Market Closed as of 24 Jun 2026, 04:00 pm ET

85/100

AUPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

85/100

AUPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AUPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AUPH Price Action

Last 7 days

15.2%

Last 30 days

22.2%

Last 90 days

27.4%

Trailing 12 Months

131.1%

AUPH RSI Chart

AUPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AUPH Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

8.02

Price/Sales (Trailing)

8.02

EV/EBITDA

15.35

Price/Free Cashflow

14.33

AUPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AUPH Fundamentals

AUPH Revenue

Revenue (TTM)

298.3M

Rev. Growth (Yr)

24.4%

Rev. Growth (Qtr)

0.77%

AUPH Earnings

Earnings (TTM)

298.2M

Earnings Growth (Yr)

47.17%

Earnings Growth (Qtr)

-83.7%

AUPH Profitability

Operating Margin

89.74%

EBT Margin

44.83%

Return on Equity

52.54%

Return on Assets

41.19%

Free Cashflow Yield

6.98%

AUPH Investor Care

Buy Backs (1Y)

7.43%

Diluted EPS (TTM)

2.17

AUPH Alerts

  • 1 major insider buys recently.
  • Big jump in Earnings (Y/Y)
Revenue & Growth

How Aurinia Pharmaceuticals Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026298.3M---
2025247.3M260.1M265.8M283.1M
2024191.4M207.1M220.4M235.1M
2023146.8M160.1M158.9M175.5M
202266.3M87.9M129.0M134.0M
202149.0M47.9M46.7M45.6M
2020318.0K318.0K25.2M50.1M
2019426.8K390.5K354.3K318.0K
2018429.3K440.5K451.8K463.0K
2017---418.0K
2016---173.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Aurinia Pharmaceuticals Inc

AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
 CEO
 WEBSITEauriniapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES300

Aurinia Pharmaceuticals Inc Frequently Asked Questions

AUPH is the stock ticker symbol of Aurinia Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jun 24 2026, market cap of Aurinia Pharmaceuticals Inc is 2.39 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Jun 24 2026, AUPH's PE ratio (Price to Earnings) is 8.02 and Price to Sales (PS) ratio is 8.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AUPH PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Aurinia Pharmaceuticals Inc has provided 0.218 (multiply by 100 for percentage) rate of return.